Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
FerGene has launched with more than $570 million in funding from Ferring Pharmaceuticals and Blackstone Life Sciences to bring to market nadofaragene firadenovec, a bladder cancer gene therapy. Most of the money—$400 million—comes from Blackstone, an investment firm. Ferring licensed the adenovirally mediated interferon alfa-2b gene therapy last year from FKD Therapies, which had bought it from Merck & Co. in 2011. Ferring later filed for US approval of the treatment.
This article has been sent to the following recipient: